Valuation: Lakefront Biotherapeutics NV

Market Cap 1.51B 1.74B 1.41B 1.29B 2.44B 166B 2.47B 16.52B 6.48B 82.82B 6.54B 6.39B 274B P/E 2026 *
-10.7x
P/E 2027 * -8.1x
Enterprise Value -476M -549M -443M -408M -770M -52.21B -778M -5.21B -2.04B -26.12B -2.06B -2.02B -86.52B EV / Sales 2026 *
-33.4x
EV / Sales 2027 * -10.5x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day-1.29%
1 week-6.76%
Current month-4.11%
1 month-14.94%
3 months-5.92%
6 months-20.00%
Current year-18.29%
1 week 22.88
Extreme 22.88
24.46
1 month 22.88
Extreme 22.88
27.12
Current year 22.62
Extreme 22.62
30.72
1 year 22.62
Extreme 22.62
32.74
3 years 20
Extreme 20
39
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Director

137 0.0002%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%-6.76%-20.45%-42.06% 1.76B
+0.90%-2.33%+0.68%+13.87% 48B
+1.98%+9.05%+413.94%+532.17% 41.13B
+3.44%-4.65%+28.34%+8.81% 37.56B
+1.40%+0.10%+6.61%+61.93% 35.91B
+2.42%+5.72%+12.38%+44.79% 29.86B
-0.16%-3.11% - - 16.12B
+2.20%+0.48%+34.71%+127.15% 16.05B
+1.25%+1.52%+4.62%+18.26% 13.76B
+4.25%-8.23%-1.49%-35.46% 12.1B
Average +1.64%-1.35%+53.26%+81.05% 25.23B
Weighted average by Cap. +1.88%-0.05%+81.71%+119.57%

Financials

2026 *2027 *
Net sales 14.24M 16.44M 13.27M 12.21M 23.05M 1.56B 23.31M 156M 61.23M 782M 61.75M 60.39M 2.59B 46.09M 53.21M 42.96M 39.51M 74.6M 5.06B 75.43M 505M 198M 2.53B 200M 195M 8.38B
Net income -811M -936M -756M -695M -1.31B -89B -1.33B -8.88B -3.49B -44.53B -3.52B -3.44B -147B -238M -275M -222M -204M -385M -26.11B -389M -2.6B -1.02B -13.06B -1.03B -1.01B -43.26B
Net Debt -1.98B -2.29B -1.85B -1.7B -3.21B -218B -3.25B -21.73B -8.53B -109B -8.6B -8.41B -361B -1.99B -2.3B -1.86B -1.71B -3.23B -219B -3.26B -21.84B -8.57B -110B -8.64B -8.45B -363B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
26-08-05 €22.88 -1.29% 89,429
26-08-04 €23.18 -1.28% 105,164
26-08-03 €23.48 -1.59% 93,899
26-07-31 €23.86 -1.00% 94,021
26-07-30 €24.10 -1.79% 87,672
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
22.88EUR
Average target price
30.28EUR
Spread / Average Target
+32.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock